Depo-Provera Meningioma Injury Lawyers
Recent scientific studies have concluded that medroxyprogesterone acetate, commonly used under the brand name Depo-Provera, is strongly linked to the development of intracranial meningiomas. If you received Depo-Provera injections for a year or more and have been diagnosed by a medical provider with an intracranial meningioma, you may be eligible to seek compensation.
Depo-Provera and its generic forms are contraceptive injections that patients inject every three months for birth control. The Food and Drug Administration (FDA) approved Depo-Provera for use as a contraceptive in 1992. Depo-Provera is a highly effective contraceptive favored by women for its ease of use: it does not require a patient to take a pill every day.
Depo-Provera, however, contains a significant amount of progestin, which is a synthetic version of the naturally occurring hormone progesterone. Large pharmaceutical companies such as Pfizer (the main Defendant in the litigation) either knew or, based on the medical literature, should have known, of the strong association between progesterone and meningiomas for many years. Pfizer and others should have been doing everything they could to protect patients but chose to put profits ahead of patient safety.
A patient’s development of an intracranial meningioma can dramatically alter their life. For example, meningiomas are brain tumors and as the tumor grows in size, so too will the impact on a person’s life. Meningiomas can affect a person’s vision and speech, cause headaches, impact a person’s ability to drive, and can even result in strokes or seizures. A patient diagnosed with an intracranial meningioma may also have the need for serious medical interventions including a craniotomy, which is a surgery in which a person’s skull is opened and their brain is directly exposed.
If you took Depo-Provera for more than one year and have been diagnosed with an intracranial meningioma, call the attorneys at Saltz Mongeluzzi Bendesky or fill out the online contact form for a free case evaluation.
Unmatched Experience
Saltz Mongeluzzi Bendesky is actively pursuing litigation against Pfizer and others, for failing to protect patients despite the known risks of Depo-Provera. Led by partner Larry Cohan, the firm represents patients who have been diagnosed with an intracranial meningioma and have at least one year of use of Depo-Provera injections.
Larry himself is a leader in complex mass tort cases, including those relating to pharmaceuticals. Over his career, Larry has represented hundreds of victims of vaccine injuries and has collected well in excess of $100 million of compensation for these clients. Larry also served on the Plaintiffs’ Steering Committee in the Ethicon Morcellator medical device litigation, In Re: Power Morcellator Products Liability Litigation, MDL No. 2652. Larry and his team have also represented individuals injured by Mirena IUDs, Pinnacle hip implants, Alloderm hernia implants, NexGen knee implants, Baxter kidney dialysis components, and more.
Unmatched Commitment
Saltz Mongeluzzi Bendesky partner Larry Cohan has fought for decades on behalf of people hurt by corporate negligence and wrongdoing. The firm’s trial lawyers have unique experience handling complex product liability and pharmaceutical cases and have represented victims of corporate negligence involving a variety of defective medical devices, including hip devices, knee devices, kidney dialysis devices, and devices used in hysterectomies.
In addition to work on pharmaceuticals and medical devices, Saltz Mongeluzzi Bendesky attorneys regularly handle cases on behalf of victims of asbestos, benzene, and lead poisoning, and have represented those harmed by herbicides such as Paraquat and toxins like PFAS. Partners Larry Cohan and Josh Cohan currently sit on the Plaintiffs’ Steering Committee in the PFAS Water Contamination Multidistrict Litigation.
Depo-Provera Lawsuit Update
Currently, Depo-Provera lawsuits have been consolidated in the U.S. District Court for the Northern District of Florida for pretrial proceedings. The case is Multidistrict Litigation No. 3140, Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation. A Multidistrict Litigation (MDL) is formed when similar cases from across the country are consolidated and transferred to one court and a single judge. The case is before United States District Judge M. Casey Rodgers. Early in the litigation the primary Defendants including Pfizer have filed a motion for summary judgment based upon federal preemption. The court heard oral arguments on the preemption motion on September 29, 2025. Plaintiffs and their counsel are awaiting the court’s decision with regard to the defendants’ early challenge.
Contact Us Today
If you or a loved one have been diagnosed with an intracranial meningioma and have taken Depo-Provera injections for a year, contact Saltz Mongeluzzi Bendesky today.